<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>164-DEFEROXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ASCORBIC ACID" rxcui="1151">
<ATC code="A11GA" />
<ATC code="A11GA01" />
<ATC code="A11GB" />
<ATC code="A11GB01" />
<ATC code="G01AD03" />
<ATC code="S01XA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>With large doses of the ascorbic acid and by intravenous route: 

cardiac function anomalies, even acute heart failure (generally reversible by ending administration of the Vitamin C).</DESCRIPTION>
<SEVERITY>Precaution for use:</SEVERITY>
<COMMENT>In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>164-DEFEROXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperchelation</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
